First-in-class biologic maintenance therapy approved for severe asthma – ModernMedicine

First-in-class biologic maintenance therapy approved for severe asthma
ModernMedicine
Nucala, developed by GlaxoSmithKline, is an interleukin-5 (IL-5) antagonist monoclonal antibody that reduces the production and survival of esosinophils, which are one of the inflammatory cell types involved in asthma. The biologic is to be …